Modular Linker Molecules for Targeted Immune Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting the immune response in cancer and infectious diseases are limited in specificity and efficiency, with existing linker molecules requiring complex synthesis and prone to side effects, and there is a need for improved ways to recruit natural antibodies to effectively combat cancer cells and pathogens.
Innovation Solution
Development of novel linker molecules with optimized spacer groups to control the positioning of carbohydrate molecules relative to nucleic acid aptamers or biotin, enhancing immune recruitment while minimizing side effects, using a simpler synthesis process that avoids 'click chemistry' and labile components, and allows for scalable pharmaceutical manufacture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing linker molecules are used to target immune response, then immune recruitment can be achieved, but the synthesis becomes complex and side effects increase
Solution Approach 1:
The linker molecule is divided into distinct functional modules: a first binding moiety (carbohydrate) that binds to natural antibodies, a second binding moiety (aptamer or antibody) that targets the specific antigen, and a spacer group that positions these moieties optimally. This segmentation allows each component to be optimized independently while simplifying the overall synthesis approach.
Solution Approach 2:
The patent introduces standardized intermediary building blocks and coupling methods that facilitate modular assembly of the linker components. The spacer acts as an intermediary element that connects the two binding moieties with controlled geometry, enabling systematic synthesis rather than complex de novo construction.
2Reliability
If existing linker molecules are used to target immune response, then immune recruitment can be achieved, but manufacturing scalability is reduced
Solution Approach 1:
The modular segmented structure of the linker with standardized components enables parallel synthesis and automated assembly processes, significantly improving manufacturing scalability while maintaining the immune recruitment efficacy through preserved functional geometry.
Solution Approach 2:
The patent systematically varies parameters such as spacer length, carbohydrate type, and aptamer sequence to optimize immune recruitment while establishing a platform that can efficiently produce multiple variants for different therapeutic indications, thereby improving both efficacy and manufacturing scalability.
3Ease of manufacture
If spacer groups are not optimized in linker molecules, then synthesis is simpler, but the positioning of binding moieties is poor reducing immune recruitment efficiency
Solution Approach 1:
The patent systematically optimizes spacer parameters including length, flexibility, and chemical composition to achieve precise positioning of binding moieties. This parameter optimization enhances immune recruitment efficiency while maintaining synthetic accessibility through well-established chemical methodologies.
Solution Approach 2:
The spacer groups are pre-designed with specific geometric and chemical properties that automatically position the binding moieties in optimal orientations for immune complex formation. This preliminary design of the spacer structure eliminates the need for complex post-synthesis adjustments while ensuring precise positioning.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel linker molecules effectively recruit natural antibodies to target cancer cells and pathogens, enhancing immune response with improved therapeutic efficacy and manufacturing efficiency, while avoiding complex synthesis and potential side effects.
Implementation Method 1
F represents a carbohydrate molecule capable of binding to a human anti-alpha-galactosyl antibody
Implementation Method 2
L represents a binding moiety selected from a nucleic acid aptamer or biotin
Data Source
AI summary
The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.